RBC Capital analyst Kennen MacKay said Ra Pharmaceuticals (NASDAQ: RARX) Zilucoplan gMG data should impress even the skeptics and suggests while it is still several years from market, Alexion Pharma (NASDAQ: ALXN) could consider outright buying RARX.

"Given ALXN’s focus on Soliris/ALXN1210 expansion into gMG and additional potential mechanisms to target the gMG market (SyntImmune’s FcRn-targeted antibody) we anticipate that as RARX gets closer to commercialization ALXN could have strategic interest in a RARX acquisition, with sufficient financial flexibility to pursue a deal," he comments.